Pegfilgrastim

From Wikipedia, the free encyclopedia
  (Redirected from Neulasta)
Jump to: navigation, search
Pegfilgrastim
Systematic (IUPAC) name
N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
Clinical data
Trade names Neulasta
AHFS/Drugs.com monograph
MedlinePlus a607058
Pregnancy cat.
Legal status
Pharmacokinetic data
Half-life 15-80 hrs
Identifiers
CAS number 208265-92-3 YesY
ATC code L03AA13
DrugBank DB00019
UNII 3A58010674 YesY
KEGG D06889 YesY
ChEMBL CHEMBL1201568 N
Chemical data
Formula C845H1343N223O243S9 + PEG 
Mol. mass 39000 g/mol
 N (what is this?)  (verify)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[1]

Amgen manufactures pegfilgrastim under the brand name Neulasta, which was mainly worked on by Martine Allard, while Roche manufactures it under the name Neulastim. In India it is also marketed by Abbott Healthcare under the brand name Imupeg. The drug is prepared by coupling a 20 kDa polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[2][3]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]

See also[edit]

PEGylation

External links[edit]

References[edit]

  1. ^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136-137.
  2. ^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.
  3. ^ a b Drugs.com: Pegfilgrastim